Funda Suer Joins Orchid as Executive VP and Lab Medical Director, Bringing Expertise to Reproductive Genetic Testing for Healthier Futures
Funda Suer Joins Orchid as Executive VP and Lab Medical Director, Bringing Expertise to Reproductive Genetic Testing for Healthier Futures
Orchid is at the forefront of reproductive genetic testing, offering the world's only commercially available 30 whole genome sequencing reports for embryos created during IVF. Reading over 99% of an embryo's genome —significantly surpassing the industry standard of 0.25%. Orchid's reports obtain over 100 times the data, enabling the detection of conditions previously undetectable in embryos and providing superior results for traditional screens. This includes some genetic forms of birth defects, neurodevelopmental disorders, hereditary cancers, and more.SAN FRANCISCO, Sept. 3, 2024 /PRNewswire/ -- Orchid, a reproductive technology company offering the world's only commercially available whole genome embryo screening, is thrilled to announce the appointment of Dr. Funda Suer as its new executive president and medical Director. Dr. Suer, a renowned expert in genetic diagnostic and reproductive health, will be instrumental in advancing the laboratory's mission to help couples achieve healthier pregnancies and healthier babies.
舊金山，2024年9月3日/美通社/-- Orchid是一家生殖技術公司，提供全球唯一商業化可用的全基因組胚胎篩查，並非常高興地宣佈任命Funda Suer博士爲其新的執行總裁和醫療董事。Funda Suer博士是遺傳診斷和生殖健康領域的知名專家，將在推進實驗室幫助夫婦實現更健康的妊娠和嬰兒的使命中發揮重要作用。
With a distinguished career in genetics and a passion for improving reproductive outcomes, Funda Suer brings a wealth of experience to Orchid. She has a proven track record of leading innovative research and clinical diagnostics and implementing cutting-edge technologies to enhance genetic testing processes and results.
Funda Suer在遺傳學領域擁有卓越的職業生涯，並對改善生殖結果充滿激情，爲Orchid帶來了豐富的經驗。她在領導創新研究和臨床診斷以及實施尖端技術以提升遺傳測試流程和結果方面有着卓越的成績記錄。
"I am incredibly excited to join Orchid and contribute to our shared vision of ensuring healthier babies for families," said Funda Suer. "Our commitment to providing accurate, reliable, and compassionate genetic testing services is more important than ever. I look forward to working with our talented team to make a meaningful difference in the lives of couples and their future generations."
「我非常興奮能夠加入Orchid，併爲確保家庭擁有更健康的嬰兒做出貢獻，」Funda Suer表示。「我們致力於提供準確、可靠和充滿同情心的遺傳測試服務，比以往任何時候都更重要。我期待與我們才華橫溢的團隊共同改變夫婦及其未來世代的生活。」
Orchid is at the forefront of reproductive genetic testing, offering the world's only commercially available 30 whole genome sequencing reports for embryos created during IVF. Reading over 99% of an embryo's genome —significantly surpassing the industry standard of 0.25%. Orchid's reports obtain over 100 times the data, enabling the detection of conditions previously undetectable in embryos and providing superior results for traditional screens. This includes some genetic forms of birth defects, neurodevelopmental disorders, hereditary cancers, and more.
Orchid處於生殖遺傳測試的前沿，爲經過試管嬰兒產生的胚胎提供全球唯一的30個全基因組測序報告。讀取超過99％的胚胎基因組--明顯超過行業標準的0.25％。Orchid的報告獲得超過100倍的數據，使其能夠檢測以前在胚胎中無法檢測到的疾病，併爲傳統篩查提供優越的結果。這包括一些遺傳性出生缺陷、神經發育障礙、遺傳性癌症等。
Under Funda Suer's leadership, the laboratory aims to enhance its offerings by integrating the latest advancements in genetic science and technology. This includes expanding testing capabilities, improving data accuracy, and ensuring that every patient receives the highest level of support and guidance throughout their reproductive journey.
在Funda Suer的領導下，實驗室旨在通過整合遺傳科學和技術的最新進展來提升其服務。這包括擴展測試能力，提高數據準確性，並確保每位患者在其生殖旅程中獲得最高水平的支持和指導。
"We are delighted to welcome Funda Suer to our team," said Noor Siddiqui, CEO and Founder of Orchid. "With her expertise and visionary approach, we are confident that Orchid will continue to lead the way in preimplantation genetic testing and profoundly impact the lives of the families we serve."
"我們非常高興歡迎Funda Suer加入我們的團隊，" Orchid的CEO和創始人Noor Siddiqui說。"憑藉她的專業知識和遠見，我們相信Orchid將繼續引領圍殖入前基因檢測，深刻影響我們所服務的家庭的生活。"
Orchid's whole genome embryo report offers the most data for individuals going through IVF interested in mitigating the maximum amount of genetic risk. Orchid whole genome embryo reports are available nationwide at IVF centers of excellence in San Francisco, Los Angeles, Chicago, Austin, Atlanta, Dallas, Denver, Detroit, Miami, Milwaukee, Minneapolis, Philadelphia, Princeton, St. Louis, and Washington, D.C.
Orchid的全基因組胚胎報告爲通過試管嬰兒技術進行治療的個人提供最大程度減少遺傳風險的數據。Orchid全基因組胚胎報告在舊金山、洛杉磯、芝加哥、奧斯汀、亞特蘭大、達拉斯、丹佛、底特律、邁阿密、密爾沃基、明尼阿波利斯、費城、普林斯頓、聖路易斯和華盛頓特區的卓越試管嬰兒中心全國範圍內提供。
About Orchid:
關於Orchid:
Orchid is a reproductive technology company on a mission to extend the healthspan of the next generation. Orchid offers prospective parents a clear and comprehensive understanding of their potential child's genetic health.
Orchid是一家生殖技術公司，其使命是延長下一代的健康壽命。Orchid爲潛在父母提供對他們潛在孩子的遺傳健康狀態的明確和全面的了解。
SOURCE ORCHID
來源：ORCHID
譯文內容由第三人軟體翻譯。
